News | May 19, 2023
Venus Remedies recognized for R&D excellence by DSIR
Leading Research-driven Pharma Company Combats Antibiotic Resistance and Demonstrates Innovation in Medical Solutions
Leading Research-driven Pharma Company Combats Antibiotic Resistance and Demonstrates Innovation in Medical Solutions
The additional $50 million will go towards venture capital firms that specialize in near- and long-term healthcare solutions for patients in low- and middle-income countries
Specialty Chemicals grew 38% YoY for FY23
Metronidazole is an antibiotic used on the skin to treat a certain skin disorder known as rosacea
SCYNEXIS will receive an upfront payment of $90 million with future performance-based milestone payments and tiered royalties
The approved product is indicated for the treatment of adult patients with Multiple myeloma, in combination with Dexamethasone
lAIH strives to introduce appropriate interventions for nurturing an AMR innovation ecosystem in the country through cohesive efforts across the innovation pyramid
This order is subject to initial advance payment as per the agreed terms of the contract
The company expects the GMP approval from Saudi Food and Drug Authority (SFDA) to soon pave the way for marketing authorizations from the largest market in the GCC region
Standalone Q3 FY23 revenue stood at Rs. 626.5 crore as against Rs. 594.8 crore, a growth of 5% YoY
Subscribe To Our Newsletter & Stay Updated
